We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bbr7.5
Berberine Research
Likely helps
227 peer-reviewed studies
What the evidence says
Likely helps
Berberine appears to help in 16 of 20 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 1985–2026 with a typical study size of 553 participants.
Based on 227 studies · 55 meta-analyses · 89 RCTs · 67,418 total participants
Confidence
High confidence
What the studies found
16helped3unclear1didn't help· 207 more without graded effect data
InflammationSignificant improvements in blood sugar and lipids · 4-12 weeks
Mostly mechanism / observational10 studies
Cognitive function
Mostly mechanism / observational5 studies
By the numbers
Pulled from 74 studies with measurable effects
Likely real effects
82%
across studies
People studied
67k
typical study: 553 people
Strongest designs
144
55 pooled, 89 randomised
Showed benefit
80%
16/20 studies
How long studies ran
1–4 weeks
3
1–3 months
5
3+ months
3
Populations Studied
Type 2 diabetes patients6
NAFLD patients3
Cardiovascular disease patients2
Cancer patients2
Active research area
151 studies in the last 5 years · Latest meta-analysis: 2026
198520052026
1HbA1c reductionMeta-AnalysisCited 3×n=1,337 · large study2025
However, further validation of these findings is necessary through extensive clinical studies with larger sample sizes.
Miao R et al. · Phytotherapy research : PTR (2025)
Noticeable benefit
← WorseNo effectBetter →
Borderline
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
For body mass index (BMI), curcumin was more effective than resveratrol (MD -1.27, 95%Cl -2.43 to -0.03) (P < 0.05).
Curcumin, resveratrol, silymarin, and berberine can effectively improve cardio-metabolic risk factors in T2DM, and different herbal phytochemicals have different clinical advantages.
2Inflammatory biomarkers reductionMeta-AnalysisCited 12×n=1,600 · large study2023
However, more investigation and high-quality evidence must be conducted to obtain more comprehensive and generalizable results.
Vahedi-Mazdabadi Y et al. · Phytotherapy research : PTR (2023)
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
There are limitations to our findings, including low-quality studies and significant heterogeneity.
These interventions might be considered adjunct therapy to managing inflammation status.
4Total cholesterol reductionMeta-AnalysisCited 6×n=4,838 · very large study2024
Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
Hernandez AV et al. · Journal of dietary supplements (2024)
Noticeable benefit
← WorseNo effectBetter →
Products with berberine alone had less robust effects on TC (MD -12.08 mg/dL [95%CI: -21.79 to -2.37]), LDL (MD -9.26 mg/dL [95%CI: -20.31 to 1.78]), and HDL (MD 1.38 mg/dL [95%CI: -1.27 to 4.03]) but TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23]).
Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
5Glycemic control improvementMeta-AnalysisCited 14×n=5,000 · very large study2024
The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults.
6Meta-AnalysisCited 23×n=4,606 · very large study2023
This study suggests that berberine may be a promising alternative for CVDs with no serious adverse reactions.
Yang L et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology (2023)
Berberine alone significantly reduced National Institute of Health Stroke Scale (NIHSS) score, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intima-media thickness (IMT) levels than routine therapy.
Berberine plus statins significantly reduced TC, TG, LDL-C, NIHSS score, hs-CRP, TNF-α, IMT, Crouse score, and number of unstable plaques levels than routine or statins.
This study suggests that berberine may be a promising alternative for CVDs with no serious adverse reactions.
7LDL cholesterol reductionMeta-AnalysisCited 18×n=1,788 · large study2023
Berberine produces small reductions in LDL cholesterol, triglycerides, and apolipoprotein B, with potential sex-specific effects on HDL cholesterol.
Blais JE et al. · Drugs (2023)
No clear effect
← WorseNo effectBetter →
Eighteen studies (n = 1788 participants), conducted mainly in mainland China and Hong Kong (15 studies [83%]), were included with treatment durations ranging from 4 to 24 weeks.
Berberine increased HDL cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.11, 15 studies, n = 1471).
Notably, the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (- 0.07 mmol/L, 95% CI - 0.16 to 0.02).
9Clinical efficacy rate improvementMeta-AnalysisCited 6×n=952 · large study2024
BBR demonstrates substantial efficacy in treating UC without causing severe adverse reactions and may serve as a viable complementary therapy.
Li J et al. · PloS one (2024)
Noticeable harm
← WorseNo effectBetter →
Likely real
BBR considerably improved the clinical efficacy rate (RR = 1.22, 95% CI [1.15, 1.30], P < 0.00001), attenuated the Baron score (SMD = -1.72, 95% CI [-2.30, -1.13], P < 0.00001) and reduced the DAI score (SMD = -2.93, 95% CI [-4.42, -1.43], P < 0.00001).
Additionally, it ameliorated clinical symptoms (SMD = -2.74, 95% CI [-3.45, 2.02], P < 0.00001), diminished inflammatory responses (SMD = -1.59, 95% CI [-2.14, 1.04], P < 0.00001), and modulated immune reactions (SMD = 1.06,95% CI [0.24,1.87], P <0.00001).
Nonetheless, the impact of BBR on reducing adverse reactions was not statistically significant (RR = 0.75, 95% CI [0.42, 1.33], P > 0.05).
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Zhao H et al. · Reproductive health (2021)
Compared with metformin, treatment with myo-inositol + D-chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31-93.58]).
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Myo-inositol combined with D-chiro-inositol is particularly efficacious in menstrual recovery.
13Meta-AnalysisCited 89×n=2,313 · very large study2019
The dosage and treatment duration of Berberine and patients' age may modify the effect.
Liang Y et al. · Endocrine journal (2019)
We calculated weighted mean differences (WMD) and 95% confidence interval (CI) for fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated haemoglobin (HbA1c) levels.
The pool data showed that Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups.
Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years.
Higher quality studies are needed to provide more high quality evidence.
Zhang LS et al. · The American journal of Chinese medicine (2019)
The results of meta-analysis showed that compared with the placebo group, berberine could significantly reduce the total cholesterol and low-density lipoprotein levels and elevate the high density lipoprotein level ( P<0.05 ).
Compared with the simvastatin group, berberine was effective only in reducing the level of triglyceride ( MD=-0.37 , 95% CI: - 0.66, - 0.07, P=0.02 ).
Compared with the simvastatin group, berberine plus simvastatin was more effective in reducing the level of triglyceride ( MD=-0.33 , 95% CI: - 0.46, - 0.20, P<0.00001 ) and total cholesterol ( MD=-0.36 , 95% CI: - 0.60, - 0.12, P=0.003 ).
16Meta-AnalysisCited 319×n=2,569 · very large study2015
This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect.
Lan J et al. · Journal of ethnopharmacology (2015)
This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect.
Considering the relatively low cost compared with other first-line medicine and treatment, berberine might be a good alternative for low socioeconomic status patients to treat type 2 DM, hyperlipidemia, hypertension over long time period.
Due to overall limited quality of the included studies, the therapeutic benefit of berberine can be substantiated to a limited degree.